Literature DB >> 20623356

Smoking is associated with a high prevalence of microalbuminuria in hypertensive high-risk patients: data from I-SEARCH.

Christian Ukena1, F Mahfoud, M Kindermann, S Gräber, I Kindermann, M Schneider, R Schmieder, P Bramlage, M Volpe, M Thoenes, M Böhm.   

Abstract

BACKGROUND: Microalbuminuria (MAU) is a marker of endothelial dysfunction and a predictor of cardiovascular events. The effects of cigarette smoking on the prevalence of MAU in a high-risk population with arterial hypertension are unclear.
METHODS: The International Survey Evaluating Microalbuminuria Routinely by Cardiologists in patients with Hypertension (I-SEARCH) documented the clinical profile of 20,364 patients with arterial hypertension and cardiovascular risk factors. In this population, 13,690 patients had no history of smoking, 4,057 patients were former smokers and 2,617 patients were current smokers.
RESULTS: The prevalence of MAU was associated with the smoking status. Consumption of 1-20 cigarettes per day leads to an increase of 6.8% in the prevalence of MAU compared to non-smokers (P < 0.001). Smoking of >20 cigarettes per day was associated with a 12.5% higher prevalence of MAU compared to non-smokers, while former smokers had a 4.7% higher prevalence of MAU. Multivariable analysis revealed that smoking was independently associated with MAU [odds ratio (OR) smoking vs. non-smoking 1.16; 95% confidence interval (CI) 1.01-1.33; P < 0.05]. Particularly, a consumption of >20 cigarettes per day was associated with high odds for MAU (OR 1.33; CI 1.01-1.75; P < 0.05). Interestingly, independently of blood pressure, the use of an angiotensin receptor blocker and an ACE was associated with significantly reduced odds ratio for MAU in the smoking group, while there was no significant association in the non-smoking group.
CONCLUSION: The prevalence of MAU in hypertensive patients is higher in smokers than in non-smokers with a strong dose dependency.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20623356     DOI: 10.1007/s00392-010-0194-y

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  27 in total

Review 1.  The health consequences of cigarette smoking. Pulmonary diseases.

Authors:  C B Sherman
Journal:  Med Clin North Am       Date:  1992-03       Impact factor: 5.456

Review 2.  The renal risks of smoking.

Authors:  S R Orth; E Ritz; R W Schrier
Journal:  Kidney Int       Date:  1997-06       Impact factor: 10.612

3.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Authors:  R Zatz; B R Dunn; T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective.

Authors:  H-H Parving; J B Lewis; M Ravid; G Remuzzi; L G Hunsicker
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

Review 7.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

8.  Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients.

Authors:  Michael Böhm; Martin Thoenes; Hans-Ruprecht Neuberger; Stefan Gräber; Jan-Christian Reil; Peter Bramlage; Massimo Volpe
Journal:  Eur Heart J       Date:  2009-04-21       Impact factor: 29.983

9.  Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease.

Authors:  Scott D Solomon; Julie Lin; Caren G Solomon; Kathleen A Jablonski; Madeline Murguia Rice; Michael Steffes; Michael Domanski; Judith Hsia; Bernard J Gersh; J Malcolm O Arnold; Jean Rouleau; Eugene Braunwald; Marc A Pfeffer
Journal:  Circulation       Date:  2007-11-19       Impact factor: 29.690

10.  Microalbuminuria and endothelial dysfunction in essential hypertension.

Authors:  R Pedrinelli; O Giampietro; F Carmassi; E Melillo; G Dell'Omo; G Catapano; E Matteucci; L Talarico; M Morale; F De Negri
Journal:  Lancet       Date:  1994-07-02       Impact factor: 79.321

View more
  4 in total

1.  Acute (but not chronic) smoking paradoxically protects the endothelium from ischemia and reperfusion: insight into the "smoking paradox".

Authors:  Monica Lisi; Saverio Dragoni; Maria Cristina Leone; Thomas Münzel; John D Parker; Tommaso Gori
Journal:  Clin Res Cardiol       Date:  2013-02-19       Impact factor: 5.460

2.  Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension.

Authors:  Felix Mahfoud; Christian Ukena; Janine Pöss; Peter Bramlage; Massimo Volpe; Martin Thoenes; Roland Schmieder; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2012-04-07       Impact factor: 5.460

Review 3.  Understanding and treating hypertension in diabetic populations.

Authors:  Massimo Volpe; Allegra Battistoni; Carmine Savoia; Giuliano Tocci
Journal:  Cardiovasc Diagn Ther       Date:  2015-10

4.  Albuminuria, Lung Function Decline, and Risk of Incident Chronic Obstructive Pulmonary Disease. The NHLBI Pooled Cohorts Study.

Authors:  Elizabeth C Oelsner; Pallavi P Balte; Morgan E Grams; Patricia A Cassano; David R Jacobs; R Graham Barr; Kristin M Burkart; Ravi Kalhan; Richard Kronmal; Laura R Loehr; George T O'Connor; Joseph E Schwartz; Michael Shlipak; Russell P Tracy; Michael Y Tsai; Wendy White; Sachin Yende
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 30.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.